U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Anti-folate receptor antibody positivity

MedGen UID:
1052725
•Concept ID:
CN377944
•
Finding
HPO: HP:6000795

Definition

The presence of autoantibodies (immunoglobulins) in the serum that react against the folate receptor in the blood circulation. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAnti-folate receptor antibody positivity

Recent clinical studies

Therapy

Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
Nwabufo CK
Cancer Chemother Pharmacol 2024 Feb;93(2):89-105. Epub 2023 Aug 18 doi: 10.1007/s00280-023-04575-y. PMID: 37594572
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN
Gynecol Oncol 2020 May;157(2):379-385. Epub 2020 Feb 18 doi: 10.1016/j.ygyno.2020.01.037. PMID: 32081463
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ
J Clin Oncol 2017 Apr 1;35(10):1112-1118. Epub 2016 Dec 28 doi: 10.1200/JCO.2016.69.9538. PMID: 28029313Free PMC Article

Prognosis

Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
Nwabufo CK
Cancer Chemother Pharmacol 2024 Feb;93(2):89-105. Epub 2023 Aug 18 doi: 10.1007/s00280-023-04575-y. PMID: 37594572
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer.
Yazaki S, Kojima Y, Yoshida H, Takamizawa S, Kitadai R, Nishikawa T, Shimoi T, Sudo K, Saito A, Okuma HS, Tanioka M, Noguchi E, Uno M, Ishikawa M, Kato T, Fujiwara Y, Ohe Y, Yonemori K
J Gynecol Oncol 2022 Nov;33(6):e82. Epub 2022 Sep 27 doi: 10.3802/jgo.2022.33.e82. PMID: 36245230Free PMC Article

Clinical prediction guides

High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer.
Yazaki S, Kojima Y, Yoshida H, Takamizawa S, Kitadai R, Nishikawa T, Shimoi T, Sudo K, Saito A, Okuma HS, Tanioka M, Noguchi E, Uno M, Ishikawa M, Kato T, Fujiwara Y, Ohe Y, Yonemori K
J Gynecol Oncol 2022 Nov;33(6):e82. Epub 2022 Sep 27 doi: 10.3802/jgo.2022.33.e82. PMID: 36245230Free PMC Article
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN
Gynecol Oncol 2020 May;157(2):379-385. Epub 2020 Feb 18 doi: 10.1016/j.ygyno.2020.01.037. PMID: 32081463
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ
J Clin Oncol 2017 Apr 1;35(10):1112-1118. Epub 2016 Dec 28 doi: 10.1200/JCO.2016.69.9538. PMID: 28029313Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Consumer resources

    Reviews

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...